Top Story

Azacitidine, lenalidomide treatment appears safe for myelodysplastic syndrome, AML

January 26, 2015

A sequential treatment combination of lenalidomide and azacitidine appeared active in and safe for patients with high-risk myelodysplastic syndrome or acute myeloid leukemia, according to study results.

Azacitidine is a hypomethylating agent that is part of standard care for patients with myelodysplastic syndrome. However, responses to the drug have only been temporary, and after the initial treatment fails, the outcomes are poor, according to the study background.

Institution Notes

University of Pittsburgh appoints director of stem cell transplantation

January 23, 2015
Warren Shlomchik, MD, has been named director of stem cell transplantation and cell therapies for the University of Pittsburgh’s division of hematology-oncology…
Adam J. Olszewski, MD In the Journals

Trend against combined-modality therapy for early-stage Hodgkin's lymphoma may impact survival

January 21, 2015
Socioeconomic factors often influenced the decision to eliminate radiation therapy from the treatment of classic non-Hodgkin’s lymphoma, according to study…
FDA News

FDA grants fast track designation to CPX-351 for AML

January 20, 2015
The FDA granted fast track designation to the experimental agent CPX-351 for treatment of elderly patients with secondary acute myeloid leukemia, the drug’s…
CME
New Advances, New Options: Evaluating the Changing Landscape of Hemophilia

New Advances, New Options: Evaluating the Changing Landscape of Hemophilia to Optimize Patient Outcomes

This activity is supported by an educational grant from Biogen Idec.

The bleeding abnormalities associated with hemophilia can have devastating consequences for patients. Recent advances…
More »
Meeting News Coverage Video
Genome editing demonstrated wide application for blood disorders

Genome editing demonstrated wide application for blood disorders

January 4, 2015
SAN FRANCISCO — Ralph Green, MD, PhD, FRCPath, medical director of the UC Davis Health System Medical…
More »
CME CNE
Low Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 1 Low Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain MDS…
More »

Filter By:

Mikkael A. Sekeres In the Journals

Azacitidine, lenalidomide treatment appears safe for myelodysplastic syndrome, AML

January 26, 2015
A sequential treatment combination of lenalidomide and azacitidine appeared active in and safe for patients with high-risk myelodysplastic syndrome…
Institution Notes

University of Pittsburgh appoints director of stem cell transplantation

January 23, 2015
Warren Shlomchik, MD, has been named director of stem cell transplantation and cell therapies for the University of Pittsburgh’s division of…
Adam J. Olszewski, MD In the Journals

Trend against combined-modality therapy for early-stage Hodgkin's lymphoma may impact survival

January 21, 2015
Socioeconomic factors often influenced the decision to eliminate radiation therapy from the treatment of classic non-Hodgkin’s lymphoma…
FDA News

FDA grants fast track designation to CPX-351 for AML

January 20, 2015
The FDA granted fast track designation to the experimental agent CPX-351 for treatment of elderly patients with secondary acute myeloid leukemia, the…
Antonio C. Wolff, MD In the Journals

Marrow neoplasm risk increased after adjuvant breast cancer therapy

January 15, 2015
Outcomes for early-stage breast cancer have improved, but incomplete examination and follow-up may have underestimated subsequent risks for…
In the Journals

Prevention of HBV reactivation improved with entecavir in patients with DLBCL

January 15, 2015
The addition of entecavir to the chemotherapy regimen R-CHOP may have better efficacy than lamivudine for prevention of reactivating hepatitis B…
Ajay Gopal, MD In the Journals

Brentuximab vedotin may extend disease control in relapsed, refractory Hodgkin's lymphoma

January 14, 2015
Brentuximab vedotin may provide prolonged disease control for patients with relapsed or refractory Hodgkin’s lymphoma than other systemic…
John Sweetenham, MD, PhD EditorialPublication Exclusive

Robust data needed to settle maintenance therapy debate in hematologic malignancies

HemOnc Today, January 10, 2015
John Sweetenham, MD
The value of post-induction maintenance therapy in hematologic malignancies has gained renewed attention over the last few years.For the most part…
In the Journals

HCV with 1p36.3 mutation may contribute to cancer risk

January 8, 2015
The combination of hepatitis C virus, Ki-67 positivity and 1p36.3 deletion may be associated with the development of certain cancers, according to…
Apostolos Tsapas, MD, PhD, MSc In the Journals

MRI shows limited diagnostic efficacy for liver iron overload

January 8, 2015
MRI may be accurate in ruling out hepatic iron overload but not accurate enough to provide a definite diagnosis, according to recent study data…
More Headlines »
morganatic-roan